It is a common misconception that transgender athletes who transition from male to female have the same sexual dimorphisms and therefore the same athletic capabilities and baseline statistics as cisgendered women when competing within athletic competition. Cisgender males on average have 40% more upper body muscle/strength than cisgendered women and 30% more lower body muscle/strength than cisgendered women, although these are mere approximations which span the entire world population which is why this is not always the case. Female hormones can reduce these advantages by 5% – 10% within the body of elite athletes, but it is at the current time, as of 2023, impossible to completely reverse the advantage of biological male puberty for transgender male to female athletes. Surprisingly, hormone therapy rapidly reduces hemoglobin levels to that of cisgender women however all other baseline statistics remain relatively the same post transition when using hormone replacement therapy. Even after 36 months of treatment, virtually all other baseline levels are higher than the average cisgender female. These discoveries suggest that physical strength may be preserved in transgender women during the first 3 years of hormone replacement therapy. It should be noted, if the athlete does not go through male puberty, these male hormone induced advantages do not apply. This is because these traits are largely associated with testosterone but not entirely